of these compounds, the results confirmed that the addition of multiple sulfo groups to PSTs reduces the compounds' binding affini ties to voltagegated sodium channels. This strongly suggests that sulfo groups reduce PST toxi city, further highlighting their potential for incorporation into PSTbased drug candidates.
The use of biosynthetic enzymes to modify PSTs represents a strategy that is distinct from the chemicalsynthesis approaches more frequently used to make analogues of these natural products 12 . Although many of those synthetic efforts have been successful, they often involve long sequences of reactions and deliver low yields of products as a con sequence of the challenging architectures of the PSTs -which contain an abundance of reactive oxygen and nitrogen atoms that com plicate the use of morestandard chemical reactions. Lukowski and colleagues' find ings now offer researchers the opportunity to combine conventional synthetic chemistry with biocatalysis, using enzymes to further modify PST scaffolds obtained by synthetic routes. This could potentially streamline access to sulfated versions of these natural products. It might eventually even be possible to use this approach to make nonnatural PST analogues for evaluation as candidate therapeutics.
However, substantial barriers must be surmounted before these sulfotransferase enzymes can be fully integrated into PST syn theses. Their catalytic efficiency is very low, and they have not yet been used on a large scale -Lukowski a n d c o l l e a g u e s worked at a sub milligram scale, but multigram quanti ties of PST analogues would eventually be needed for the pre clinical development of drug candi dates. Also, the reactivity of the enzymes towards nonnatural PST scaffolds, or towards members of related toxin families, has yet to be evaluated. If the reactiv ity and selectivity of the sulfotransferases can be optimized using enzyme engineering, these biocatalysts will become powerful synthetic tools in the search for new pain therapeutics. 
nflammation can help to eliminate infection, but excessive inflammation can cause damage to the body. The sensor pro teins that trigger an inflammatory immune response must therefore be carefully regulated. Some intracellular immunesensor proteins detect components in a cell that become abnor mal or altered during a cellular crisis. Signs of cellular crisis are sometimes produced in the absence of an infection, so mechanisms are needed to prevent the proteins from trigger ing an inappropriate inflammatory response. Sharif et al. 1 report a structural study on page 338 that investigates an immunesensor protein called NLRP3, revealing that a protein called NEK7 acts as a 'licence' that enables this protein to cause inflammation.
When an immune sensor recognizes a hallmark of infection in the cytoplasm, this can activate the protein and lead to the assembly of a multiprotein complex called an inflamma some. The activation of proteins that function downstream of an inflammasome can potently drive both inflammation and cell death 2 . Different types of inflammasome can form depending on the sensor components involved. Certain inflammasomes respond to a highly specific trigger: for example, those in mammalian cells containing the sensor pro tein NLRC4 respond to the presence of the bacterial protein flagellin 3, 4 .
Proteins that are normally present in mammalian cells do not seem able to trigger the accidental formation of NLRC4containing inflammasomes, given the lack of reports of such aberrant events. By contrast, inflamma somes that contain NLRP3 are activated when NLRP3 recognizes -by an as yet unknown mecha nism -hallmarks of cellular catastrophe, such as extremely low concentrations of potassium in the cytoplasm, or signs of dysfunction in organelles called mitochondria 2 . Such events can arise from tissue damage that is un related to infection, and NLRP3 activation in such cases has been implicated as a possible cause of inflammatory diseases such as atherosclerosis.
It is widely accepted that the tightly regulated formation of NLRP3containing inflammasomes occurs in two steps. In the first step, NLRP3 is primed for action by other immunesensor proteins called TLRs, which can detect components of microorganisms. This priming step occurs in two ways 2 : NLRP3 can undergo a modification, such as the addi tion of a phosphate group or the removal of an attached ubiquitin protein. Further priming is achieved by a rise in expression of the gene that encodes NLRP3, increasing the chance that NLRP3 will detect any abnormalities. The second step, activation, then results in NLRP3 proteins binding together to form part of a discshaped inflammasome complex that is probably similar to those of other inflamma somes containing proteins of the NLR family (which includes NLRP3 and NLRC4) 5, 6 . This activation step occurs during a cellular cata strophe, but the biochemical and structural mechanisms involved are unknown.
Researchers have long sought to determine the structure of NLRP3 as it forms an inflam masome, in the hope of gaining insights into how this protein functions. However, such efforts have been unsuccessful, perhaps because unknown protein partners that interact with NLRP3 were missing from earlier attempts.
The discovery [7] [8] [9] that the enzyme NEK7 is essential for NLRP3 signalling provided a missing part of the puzzle. NEK7 regulates pro cesses that occur during cell division, such as the breakdown of the nuclearenvelope structure 10 , so it was surprising to find that it has a separate role in inflammation. This suggested that NLRP3containing inflammasome formation doesn't occur during cell division because NEK7 8, 9 . However, why such an inter action between NEK7 and NLRP3 is essential for inflammasome formation has remained elusive.
IMMUNOLOGY

A licence to kill during inflammation
To tackle this question, Sharif et al. used cryoelectron microscopy to investigate the structure of a human NLRP3 interacting with NEK7. The authors' structural data reveal that NLRP3 and NEK7 bind to form a dimer in which NLRP3 is in an inactive conformation. In this state, the LRR domain of NLRP3 has a lobed, semicircular shape (Fig. 1) , and the carboxyterminal region of NEK7 nestles in the inner curve of the LRR.
NLRP3 also contains a structure called the NACHT domain, and in the inactive NLRP3-NEK7 complex, this domain is struc turally very similar to the NACHT domain 11 of in active NLRC4. It was previously shown 5, 6, 11 that the NACHT domain of NLRC4 rotates as it transitions into an active conformation. This rotationalactivation step uncovers part of the NACHT surface, enabling inflammasome formation through a proteinassembly process called oligomerization, and generating a disc shaped NLRC4containing inflammasome 5, 6 . The authors used this information to model a hypothetical conformation for an NLRP3 containing inflammasome.
In Sharif and colleagues' model, the hypothet ical rotational activation of NLRP3 doesn't affect NEK7 binding, and NEK7 still fits into NLRP3's LRR domain in the same way as in the inac tive structure. Further more, the authors made the surprising discovery that NEK7 provides a bridge between adjacent NLRP3 proteins, by forming an interface with the LRR of the adjacent NLRP3 in the inflammasome. The ability to form such an interface suggests that NEK7 provides a licence for NLRP3 to form part of the inflammasome. It seems that this licensing event occurs independently of both the priming and rotationalactivation steps, because the authors did not include molecules that cause priming or add triggers for rotational activation in their structural studies. The results suggest a revised view of how the NLRP3 containing inflammasome is regulated, and put forward the idea that NLRP3 oligomerization requires NEK7 licens ing. Taken together with evidence from earlier studies [7] [8] [9] , it seems likely that this licence is revoked dur ing cell division.
The function of NEK7 in the NLRP3 containing inflammasome is interesting when considered in relation to the structure of the NLRC4containing inflammasome. The LRR domain of NLRC4 is longer than that of NLRP3, and makes direct contact with the LRR of the adjacent NLRC4 protein in the inflammasome 5, 6 . In an NLRP3containing inflammasome, NEK7 fulfils a similar connect ing role by making contact with adjacent LRR domains. This explains why NLRP3containing inflammasomes require NEK7 licensing, whereas NLRC4containing ones do not.
Many mysteries concerning the regulation of NLRP3containing inflammasomes remain. Perhaps future structural studies will reveal how NLRP3 modification accomplishes the priming step.
Finally, we still don't know the answer to 
